6-乙基-2-吡啶甲醛 | 153646-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-乙基-2-吡啶甲醛
• 中文别名: 6-乙基吡啶啉醛
• 英文名称: 6-ethyl-2-pyridinecarboxaldehyde
• 英文别名: 6-ethylpyridine-2-carboxaldehyde；6-Ethylpicolinaldehyde；6-ethylpyridine-2-carbaldehyde
• CAS: 153646-82-3
• 化学式: C₈H₉NO
• 分子量: 135.166
• InChiKey: ZTWDMEWZCFVRQN-UHFFFAOYSA-N

物化性质

• 沸点：
  205.4±28.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-乙基-2-吡啶甲醛 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 N-methyl-N-<(6-ethyl-2-pyridinyl)methyl>amine
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+
• 作为产物：
  描述：

  5-己烯-3-醇 在 镍 lithium aluminium tetrahydride 、 tetrafluoroboric acid 、 草酰氯 、 氢气 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 为溶剂， 反应 11.33h， 生成 6-乙基-2-吡啶甲醛
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+

文献信息

• An Additional Coordination Group Leads to Extremely Efficient Chiral Iridium Catalysts for Asymmetric Hydrogenation of Ketones
  作者：Jian-Hua Xie、Xiao-Yan Liu、Jian-Bo Xie、Li-Xin Wang、Qi-Lin Zhou

  DOI：10.1002/anie.201102710

  日期：2011.8.1

  What a turnover! An efficient chiral iridium catalyst that bears a tridentate spiro aminophosphine ligand catalyzes the asymmetric hydrogenation of ketones with excellent enantioselectivities (up to 99.9 % ee) and extremely high turnover numbers (TONs; as high as 4 550 000).

  营业额！带有三齿螺氨基膦配体的高效手性铱催化剂可催化酮的不对称氢化，具有出色的对映选择性（高达99.9％ee）和极高的周转率（TONs；高达455万）。
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Pyridine-substituted benzyl alcohols as leukotriene antagonists
  申请人：Merck Frosst Canada, Inc.

  公开号：US05506227A1

  公开（公告）日：1996-04-09

  Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

  具有I式化学式的化合物是白三烯的拮抗剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑血管痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。
• [EN] PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE<br/>[FR] DERIVES DE LA PYRIDIN-2-YL-METHYLAMINE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION COMME MEDICAMENTS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：WO1998022459A1

  公开（公告）日：1998-05-28

  (EN) The invention concerns novel pyridin-2-yl-methylamine derivatives of formula (I) in which: u represents a hydrogen atom or a methyl radical; v represents a hydrogen atom or a chlorine atom or a methyl radical; w represents a hydrogen atom or a fluorine atom or a methyl radical; x represents a hydrogen atom or a fluorine atom; y represents a chlorine atom or a methyl radical; z represents a hydrogen atom or a fluorine atom or a chlorine atom or a methyl radical; A represents a hydrogen atom or a fluorine atom or a chlorine atom; a C1-C5 alkyl radical; a fluoroalkyl radical; a cyclopropyl radical; an aromatic heterocyclic group with 5 chains; an alkoxy or alkythio group; an amine group; an amino cyclic group; an alkoxycarbonyl group. These compounds are useful as medicine in particular as antidepressant or analgesic.(FR) La présente invention concerne de nouveaux dérivés de la pyridin-2-yl-méthylamine de formule (I) dans laquelle: u représente un atome d'hydrogène ou un radical méthyl; v représente un atome d'hydrogène ou un atome de chlore ou un radical méthyl; w représente un atome d'hydrogène ou un atome de fluor ou un radical méthyl; x représente un atome d'hydrogène ou un atome de fluor; y représente un atome de chlore ou un radical méthyl; z représente un atome d'hydrogène ou un atome de fluor ou un atome de chlore ou un radical méthyl; A représente: un atome d'hydrogène ou un atome de fluor ou un atome de chlore; un radical alkyl en C1-C5; un radical fluoroalkyl; un radical cyclopropyl; un groupe hétérocyclique aromatique à 5 chaînons; un groupe alkoxy ou alkylthio; un groupe amino; un groupe amino cyclique; un groupe alkoxycarbonyl. Ces composés sont utiles comme médicaments notamment comme antidépresseurs et analgésiques.

  该发明涉及公式（I）的新型吡啶-2-基甲胺衍生物：其中，u代表氢原子或甲基基团；v代表氢原子或氯原子或甲基基团；w代表氢原子或氟原子或甲基基团；x代表氢原子或氟原子；y代表氯原子或甲基基团；z代表氢原子或氟原子或氯原子或甲基基团；A代表氢原子或氟原子或氯原子；C1-C5烷基基团；氟烷基基团；环丙基基团；带有5个链的芳香杂环基团；烷氧基或烷硫基团；胺基团；氨基环基团；烷氧羰基团。这些化合物在医学上有用，特别是作为抗抑郁剂或镇痛剂。
• KINASE INHIBITORS AND USES THEREOF
  申请人：Raeppel Stephane

  公开号：US20080255155A1

  公开（公告）日：2008-10-16

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制激酶活性的化合物、组合物和方法。本发明还提供用于治疗细胞增殖性疾病和病症的化合物、组合物和方法。